Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Kevin Bickart, MD/PhD (ucla)

Description

Summary

The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS).

The investigators intend to answer the questions:

  1. Does personalized TMS improve brain connectivity after concussion?
  2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms?
  3. Do the improvements last up to 2 months post-treatment?
  4. Are there predictors of treatment response, or who might respond the best?

Participants will undergo 14 total visits to University of California Los Angeles (UCLA):

  1. One for the baseline symptom assessments and magnetic resonance imaging (MRI)
  2. Ten for TMS administration
  3. Three for post-treatment symptom assessments and MRIs

Participants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.

Official Title

Personalized Circuit-Based Frontoamygdala Neuromodulation for Persistent Post-Concussive Symptoms

Details

The overall objective of the proposed project is to apply a well-studied and safe form of brain modulation to patients with chronic symptoms after concussion. These patients represent a vulnerable population in need of brain-targeted and personalized therapies. Chronic concussive symptoms can include emotional, physical, and cognitive problems, such as depression, anxiety, headache, dizziness, sensory sensitivities, and difficulties with memory and attention. These symptoms are costly and relatively common, representing a public health concern, yet there are no standard therapies. This is in part due to a limited understanding of the underlying cause of these symptoms.

Most concussions do not cause a visible injury to the brain based on clinical-grade brain imaging. Using research-grade brain imaging however, the investigators have identified an overactive brain circuit in patients who have more chronic symptoms after concussion and more severe forms of traumatic brain injury. Interestingly, this brain circuit connects the frontal lobe of the brain to a deep structure in the brain, called the amygdala, which is important for generating and regulating emotions. The investigators' finding suggests that this brain circuit may be involved in chronic concussive symptoms. This is promising because the frontal lobe can be targeted with noninvasive brain modulation treatment. In fact, these preliminary findings show that inhibiting the frontal lobe at the midline, over the forehead, can decrease the activity of this brain circuit.

Whereas these preliminary findings are promising, this target location and modulation technique have not been studied in patients with concussion. Here, the investigators propose leveraging this prior work to apply the same brain modulation approach to patients with chronic symptoms after concussion. The investigators will also advance this approach to personalize the brain modulation and optimize chances of modulating the intended brain circuit by mapping each individual's brain circuits prior to treatment. The study will be conducted in patients between 18 and 65 years old who have had a mild traumatic brain injury, including concussion, and report a significant burden of symptoms up to 12 months after their injury.

Seventy-five participants will be randomly assigned to active modulation and sham modulation (or inactive in which the participant receives only a sensation of brain modulation without actual modulation) groups. The investigators hypothesize that active brain modulation, as compared to sham modulation, will cause a decrease in activity in the brain circuit that the investigators found to be abnormally overactive in their prior studies of patients with chronic concussive symptoms. Furthermore, the investigators hypothesize that this personalized approach to frontal brain modulation will cause an improvement in chronic concussive symptoms in the active modulation but not sham modulation group, and that the improvements would be greatest for participants who showed the greatest decrease in activity of the targeted brain circuit. Finally, the investigators will also have collected many other data points about each individual that would allow us to determine what individual characteristics make one more likely to respond to this type of treatment.

This would be the first study to use brain circuit mapping on an individual level to treat patients with chronic concussive symptoms. It would not only have implications in this patient population but also any population that suffers from emotion regulation problems, such as in mood and anxiety disorders. Based on the investigators' analyses of treatment response, the investigators may even be able to determine which people would be most likely to respond to this form of frontal lobe modulation prior to recommending the treatment, a key prerequisite for precision medicine. Importantly, the findings from this work would be directly relevant to military personnel because of their higher risk of incurring combined physical and psychological trauma in battle and the higher prevalence of combined post-traumatic stress disorder and chronic concussive symptoms.

Keywords

Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain Injury, Head Injury, Headache, Dizziness, Cognitive Symptom, Dysautonomia, Anxiety, Irritability; Syndrome, Depression, Post-traumatic Stress Disorder, Transcranial Magnetic Stimulation, Magnetic Resonance Imaging, Functional MRI, Personalized neuromodulation, Amygdala, Prefrontal Cortex, Brain Injuries, Traumatic Brain Injuries, Brain Concussion, Craniocerebral Trauma, Autonomic Nervous System Diseases, Neurobehavioral Manifestations, Syndrome, Wounds and Injuries, Traumatic Stress Disorders, Post-Traumatic Stress Disorders, Active cTBS, Imaginal exposure

Eligibility

You can join if…

Open to people ages 18-65

  • Mild traumatic brain injury (mTBI) defined in accord with the World Health Organization criteria in the last 12 months
  • age 18-65 at the time of the mTBI
  • high burden of post-concussive symptoms defined as a score >=20 on the Rivermead Post-Concussion Symptoms Questionnaire

You CAN'T join if...

  • objective neurologic deficits
  • ongoing or prolonged (>3 months) post-concussive symptoms from a prior mTBI within 2 years of the index injury
  • history of transcranial magnetic stimulation (TMS) therapy
  • contraindications for TMS or magnetic resonance imaging (MRI) (e.g., metallic implant other than dental, pacemaker)
  • severe mental, physical, or medical problems that would impede participation or pose a risk for the planned intervention (e.g., liver, kidney, or heart disease, uncontrolled diabetes or hypertension, malignancy, psychosis, previous seizure, pregnancy)
  • active alcohol or illicit drug abuse
  • inability to speak and read English

Location

  • UCLA
    Westwood California 90095 United States

Lead Scientist at University of California Health

  • Kevin Bickart, MD/PhD (ucla)
    Assistant Professor-in-Residence, Neurology, Medicine. Authored (or co-authored) 13 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT06073886
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated